{"title":"Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan","path":"/2026/02/05/eisai-and-henlius-enter-into-exclusive-commercial-license-agreement-for-anti-pd-1-antibody-serplulimab-in-japan/","site":"https://laotiantimes.com","atUri":"at://did:plc:svcthvzunxmjidtlw23zva6n/site.standard.document/3me4imvhycmq2","publishedAt":"2026-02-05T11:44:00Z","tags":"Cision PR Newswire"}